© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 13, 2014
Suresh S. Ramalingam, MD, discussed the potential of veliparib as a treatment for patients with squamous cell NSCLC in an interview with Targeted Oncology.
Combination therapies with agents such as indoleamine 2,3-dioxygenase (IDO) inhibitors may have the potential to synergize with immunotherapeutic approaches to improve immune function against tumor cells.
Peter Hammerman, MD, PhD, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the future treatment of squamous cell lung cancer.
Increasing knowledge of the diverse pathologic and molecular phenotypes in non-small cell lung cancer (NSCLC) has driven a more complex treatment algorithm in recent years.
Benjamin P. Levy, MD, comments on the role of chemotherapy in the treatment of lung cancer.
Abraham Chachoua, MD, discusses some challenges of treating patients with lung cancer.
Howard (Jack) West, MD, is the medical director of the Thoracic Oncology Program at Swedish Cancer Institute and president and CEO of Global Resource for Advancing Cancer Education.
As with many cancers, early detection (before the onset of symptoms) offers the possibility for less expensive treatment and better outcomes in patients with non-small cell lung cancer (NSCLC).